FATE THERAPEUTICS INC Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss
FATE THERAPEUTICS INC (FATE) had Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss of $499.00 thousand as of 2023-09-30, per its 10-Q filed 2023-11-08.
Discontinued › Notes › Investments › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss · last filed 2023-11-08
- 2023-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $499.00K.
- 2023-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $598.00K.
- 2023-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $787.00K.
- 2022-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss $1.90M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss |
|---|---|
| 2023-09-30 | $499.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $598.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $787.00K 10-Q · filed 2023-05-03 |
| 2022-12-31 | $1.90M 10-Q · filed 2023-11-08 |
| 2022-09-30 | $3.25M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $3.42M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $2.86M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $763.00K 10-K · filed 2023-02-28 |
| 2020-12-31 | $87.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |